Haemonetics Corporation (HAE) - Total Liabilities
Based on the latest financial reports, Haemonetics Corporation (HAE) has total liabilities worth $1.60 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Haemonetics Corporation - Total Liabilities Trend (1992–2026)
This chart illustrates how Haemonetics Corporation's total liabilities have evolved over time, based on quarterly financial data. See Haemonetics Corporation (HAE) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Haemonetics Corporation Competitors by Total Liabilities
The table below lists competitors of Haemonetics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
By health
SHE:300146
|
China | CN¥2.60 Billion |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
USA | $287.74 Million |
|
Hub Group Inc
NASDAQ:HUBG
|
USA | $1.15 Billion |
|
Maanshan Iron & Steel Co Ltd
SHG:600808
|
China | CN¥45.19 Billion |
|
Hycroft Mining Holding Corporation
NASDAQ:HYMC
|
USA | $46.10 Million |
|
Legend Holdings Corporation
F:1PC
|
Germany | €665.71 Billion |
|
Feng Tay Enterprises Co Ltd
TW:9910
|
Taiwan | NT$24.87 Billion |
|
Qi An Xin Technology Group Inc
SHG:688561
|
China | CN¥6.56 Billion |
Liability Composition Analysis (1992–2026)
This chart breaks down Haemonetics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Haemonetics Corporation market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Haemonetics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Haemonetics Corporation (1992–2026)
The table below shows the annual total liabilities of Haemonetics Corporation from 1992 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $1.50 Billion | -7.85% |
| 2025-03-31 | $1.63 Billion | +31.93% |
| 2024-03-31 | $1.24 Billion | +10.64% |
| 2023-03-31 | $1.12 Billion | +0.59% |
| 2022-03-31 | $1.11 Billion | +2.03% |
| 2021-03-31 | $1.09 Billion | +60.04% |
| 2020-03-31 | $680.00 Million | +12.05% |
| 2019-03-31 | $606.90 Million | +25.16% |
| 2018-03-31 | $484.91 Million | -2.84% |
| 2017-03-31 | $499.10 Million | -16.42% |
| 2016-03-31 | $597.13 Million | -9.11% |
| 2015-03-31 | $657.00 Million | -3.56% |
| 2014-03-31 | $681.23 Million | -1.65% |
| 2013-03-31 | $692.69 Million | +294.57% |
| 2012-03-31 | $175.56 Million | +19.32% |
| 2011-03-31 | $147.13 Million | -8.63% |
| 2010-03-31 | $161.02 Million | +46.64% |
| 2009-03-31 | $109.81 Million | -4.32% |
| 2008-03-31 | $114.76 Million | +23.28% |
| 2007-03-31 | $93.09 Million | -11.26% |
| 2006-03-31 | $104.89 Million | -6.86% |
| 2005-03-31 | $112.62 Million | -11.77% |
| 2004-03-31 | $127.64 Million | -6.12% |
| 2003-03-31 | $135.97 Million | +6.15% |
| 2002-03-31 | $128.10 Million | -1.31% |
| 2001-03-31 | $129.80 Million | -9.02% |
| 2000-03-31 | $142.67 Million | +6.07% |
| 1999-03-31 | $134.50 Million | -5.28% |
| 1998-03-31 | $142.00 Million | +44.60% |
| 1997-03-31 | $98.20 Million | +38.70% |
| 1996-03-31 | $70.80 Million | -18.90% |
| 1995-03-31 | $87.30 Million | +24.89% |
| 1994-03-31 | $69.90 Million | +30.41% |
| 1993-03-31 | $53.60 Million | -1.11% |
| 1992-03-31 | $54.20 Million | -- |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more